Drug Trial Radar · NCT05367388
A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian Participants
Last checked: Nov 19, 2026Latest source record: Jun 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
48
Planned (sponsor's estimate)
Start
May 20, 2022
Primary completion
Nov 2022
Study completion Dec 2022
Sponsor
- Lead sponsor
- Apollomics Inc.Industry
- Sponsor type
- Industry
- First posted
- May 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, open-label, multi-center, randomized, 2-period, adaptive design, crossover study to assess the bioequivalence of APL-101 (Vebreltinib) capsules and PLB-1001 (Bozitinib) capsules. The treatments to be administered orally in this study include: * Treatment A (reference): Two 100 mg APL-101 (Vebreltinib) capsules (200 mg dose), manufactured for Apollomics, Inc * Treatment P (test): Two 100 mg PLB-1001 (Bozitinib) capsules (200 mg dose), manufactured for Beijing Pearl Biotechnology Co., Ltd. APL-101 capsules (Treatment A) and PLB-1001 capsules (Treatment P) are similar drug products.
Conditions
- Bioequivalence
Interventions
APL-101Drug
APL-101 (Vebreltinib) is an orally available small molecule, which is a tyrosine kinase inhibitor (TKI) for the mesenchymal epithelial transition protein tyrosine kinase receptor (c-Met) with high selectivity and potency. The treatments to be administered in this study include: • Treatment A (reference): Two 100 mg APL-101 (Vebreltinib) capsules (200 mg dose), manufactured for Apollomics, Inc.
PLB-1001Drug
PLB-1001 (Bozitinib) is a chemical drug category 1.1 innovative drug. It is a highly effective and highly selective c-Met tyrosine kinase inhibitor. The treatments to be administered in this study include: • Treatment P (test): Two 100 mg PLB-1001 (Bozitinib) capsules (200 mg dose), manufactured for Beijing Pearl Biotechnology Co., Ltd.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the plasma concentration versus time curve (AUC)Time frame: Day 1 to Day 14
- Maximum observed plasma concentrationTime frame: Day 1 to Day 14
Locations
1 site in 1 country. Site status is shown where the registry gives one.
New Zealand Clinical Research
Auckland, New Zealand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.